Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Protocol No
WEILLCORNELL-AMY2006-DPD
Phase
II
Summary

The purpose of this study is to assess the tolerability and safety of an investigational combination of drugs in relapsed/refractory AL amyloidosis.

Description
DPd in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL